Calcium homeostasis depends on the reabsorption of bone by osteoclasts and the development of bone by osteoblasts. Imbalance between these two metabolisms leads to osteoporosis. Osteoporosis is a health condition characterized by low bone density, making them fragile and more risk of bone fracture. Osteoporosis develops gradually over several years and is often diagnosed by the sudden impact of bone fracture. Thus, the mechanisms that control communication between osteoclasts and osteoblasts are important for the bone metabolism. The etiology of osteoporosis is related to hormonal factors, the use of certain drugs (eg, glucocorticoids), cigarette smoking, low physical activity, low intake of calcium and vitamin D, race, small body size, and a personal or a family history of fracture. Biochemical markers of tissue turnover are increasingly used for the early diagnosis of the osteoporosis. In addition, such markers may provide additional information for understanding the pathology of disease. Several markers such as amino-terminal propeptide (PINP), β-isomerized C-terminal telopeptides, 25-hydroxy (OH) Vitamin (25-OH-VD), 25 hydroxyvitamin D and so on have been identified to be associated with the bone metabolism and osteoporosis. Detecting the quantity of these marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
Genemedi supplies antibodies and antigens for one metabolism testing for a wide selection of choices (please see below).
amino-terminal propeptide (PINP)
Cat No. | Antibody/Antigen Name | Expression platform | Isotypes | Bioactivity validation | Order |
GMP-PINP-Ag | Recombinant amino-terminal propeptide (PINP) (PINP, His Tag) | E.coli | Recombinant Antigen | amino-terminal propeptide (PINP) (PINP) Antibody Binding, Immunogen in Sandwich ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT |
β-isomerized C-terminal telopeptides
Cat No. | Antibody/Antigen Name | Expression platform | Isotypes | Bioactivity validation | Order |
GMP-β-CTx-Ab | Anti-β-isomerized C-terminal telopeptides (β-CTx) mouse monoclonal antibody(mAb) | Hybridoma | Mouse IgG | Human β-isomerized C-terminal telopeptides (β-CTx) protein binding, ELISA validated as capture antibody and detection antibody. Pair in β-CTxlevel test and Bone metabolism evaluation. |
25-hydroxy (OH) Vitamin
Cat No. | Antibody/Antigen Name | Expression platform | Isotypes | Bioactivity validation | Order |
GMP-25-OH-VD-Ab | 25-OH-VD Monoclonal Antibody | Hybridoma | Mouse IgG | Human 25-hydroxy (OH) Vitamin (25-OH-VD) protein binding, ELISA validated as capture antibody and detection antibody. Pair in 25-OH-VDlevel test and Bone metabolism evaluation. |
25 hydroxyvitamin D
Cat No. | Antibody/Antigen Name | Expression platform | Isotypes | Bioactivity validation | Order |
GMP-25-OH-(VD3+VD2)-Hapten; GMP-25-OH-(VD3+VD2)-Ab | Antigen: Recombinant 25 hydroxyvitamin D (25-OH-(VD3+VD2), His Tag) Antibody: Anti-25 hydroxyvitamin D (25-OH-(VD3+VD2)) mouse monoclonal antibody(mAb) | Antigen: E.coli Antibody: Hybridoma | Antigen: Recombinant Antigen Antibody: Mouse IgG | Antigen: 25 hydroxyvitamin D (25-OH-(VD3+VD2)) Antibody Binding Antibody: Human 25 hydroxyvitamin D (25-OH-(VD3+VD2)) protein binding, ELISA validated as capture antibody and detection antibody. Pair in 25-OH-(VD3+VD2) level test and Bone metabolism evaluation. |